Remestemcel-l reduces mortality in patients less than 65 years old with moderate/severe covid-19 ards: topline 60-day results from randomized controlled trial

New york, april 29, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from the randomized controlled trial of remestemcel-l in 222 ventilator-dependent covid-19 patients with moderate/severe acute respiratory distress syndrome (ards) which had been halted after the third interim analysis, as previously announced. remestemcel-l reduced mortality through day 60 by 46% in the pre-specified group below age 65, but not in patients 65 or older. remestemcel-l reduced mortality by 75% and increased days alive off mechanical ventilation in patients under age 65 when combined with dexamethasone, in comparison with controls on dexamethasone.
MESO Ratings Summary
MESO Quant Ranking